| Multiple Myeloma
Abecma vs Xpovio
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Abecma vs Xpovio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXpovio has a higher rate of injection site reactions vs Abecma based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xpovio but not Abecma, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Abecma
Xpovio
At A Glance
IV infusion
Single infusion
BCMA-directed CAR-T cell therapy
Oral
Once or twice weekly
XPO1 inhibitor
Indications
- Multiple Myeloma
- Multiple Myeloma
- Diffuse Large B-Cell Lymphoma
Dosing
Multiple Myeloma Lymphodepleting chemotherapy: cyclophosphamide 300 mg/m2 IV and fludarabine 30 mg/m2 IV for 3 days; administer ABECMA 300 to 510 x 10^6 CAR-positive T cells by IV infusion two days after completion of lymphodepleting chemotherapy; premedicate with acetaminophen and an H1-antihistamine approximately 30 to 60 minutes before infusion.
Multiple Myeloma (with Bortezomib and Dexamethasone) 100 mg orally once weekly on Day 1 of each week in combination with bortezomib 1.3 mg/m2 SC once weekly and dexamethasone 20 mg orally twice weekly on Days 1 and 2.
Multiple Myeloma (with Dexamethasone) 80 mg orally on Days 1 and 3 of each week in combination with dexamethasone 20 mg orally on Days 1 and 3 of each week.
Diffuse Large B-Cell Lymphoma 60 mg orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) CRS, pyrexia, any infection, febrile neutropenia, hypogammaglobulinemia, musculoskeletal pain, hypotension, infections-pathogen unspecified, fatigue, tachycardia, diarrhea, nausea, headache, encephalopathy, dyspnea, edema
Serious infections-pathogen unspecified, pneumonia, viral infections, encephalopathy, pyrexia, sepsis
Postmarketing Immune effector cell-associated neurotoxicity syndrome (ICANS), T cell malignancies
Most common (>=20%) Fatigue, nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, weight decreased, anemia, peripheral neuropathy, upper respiratory tract infection, hyponatremia, cataract
Serious Thrombocytopenia, neutropenia, gastrointestinal toxicity (nausea, vomiting, diarrhea, weight loss), hyponatremia, serious infection (including pneumonia and sepsis), neurological toxicity, cataract
Pharmacology
ABECMA is a BCMA-directed CAR-positive T cell therapy; the CAR construct uses an anti-BCMA scFv-targeting domain linked to CD3-zeta and 4-1BB intracellular signaling domains, resulting in CAR-positive T cell proliferation, cytokine secretion, and cytolytic killing of BCMA-expressing plasma cells.
Selinexor reversibly inhibits exportin 1 (XPO1), blocking nuclear export of tumor suppressor proteins and oncogenic mRNAs, causing nuclear accumulation of tumor suppressors, downregulation of oncoproteins such as c-myc and cyclin D1, cell cycle arrest, and apoptosis of cancer cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Abecma
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Xpovio
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Abecma
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xpovio
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Abecma
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Xpovio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCell Therapy 360 Patient Assistance Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Xpovio Co-Pay CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AbecmaView full Abecma profile
XpovioView full Xpovio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.